Answers are grounded in this paper and cite their sources.
Abstract Transition metal-catalyzed asymmetric hydrogenation of ketones has been well established; however, the asymmetric hydrogenation of sterically unbiased ketones remains a formidable challenge, due to the difficulty in control of enantioselectivity. Herein, we have developed a highly practical and efficient protocol for the asymmetric hydrogenation of sterically unbiased aromatic ketones, and a series of chiral cyclic diaryl alcohols, including the key intermediate of Baloxavir (super Tamiflu), with up to 99% yield and up to 99% ee. Mechanistic investigations indicate that iridium precursor [Ir(COD)Cl]₂ could undergo an intramolecular oxidative C-H activation with the oxa-spirocyclic ligand to produce a highly rigid butterfly-shaped complex which is responsible for achieving high enantioselectivity, and X-ray diffraction analysis indicate that the ligand behaves as a tetradentate PNNC ligand, which could inhibit the toxicity of the sulfur-containing substrate to the catalyst. Preliminary DFT calculations and NCI analysis demonstrated that π-π interactions between the substrate and catalyst played a key role in the control of enantioselectivity. Furthermore, the synthetic potential of our catalytic system was verified by the gram-scale asymmetric hydrogenation, and Baloxavir intermediate was obtained with retention of enantioselectivity.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: